To dissect the specific tumor immune microenvironment (TIME) of BrMs and investigate the potential explanations for different treatment outcomes of anti-PD-1/PD-L1 based therapies, we conducted a transcriptomic analysis on paired samples from primary lung cancers and BrMs. This evidence concerns the gene PDCD1 and neoplasm.